Sugi Predict

Sugi Predict / Compounds / SCHEMBL725316

SCHEMBL725316

SCHEMBL725316

COc1cc(C(=O)c2c[nH]c(-c3ccc(C(F)(F)F)cc3)n2)cc(OC)c1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TUBB4A P04350 13/20 0.46
▸ TUBB P07437 13/20 0.46
▸ TUBA3C P0DPH7 13/20 0.46
▸ TUBA1B P68363 13/20 0.46
▸ TUBA4A P68366 13/20 0.46
▸ TUBB4B P68371 13/20 0.46
▸ TUBB3 Q13509 13/20 0.46
▸ TUBB2A Q13885 13/20 0.46
▸ TUBB8 Q3ZCM7 13/20 0.46
▸ TUBA3E Q6PEY2 13/20 0.46
▸ TUBA1A Q71U36 13/20 0.46
▸ TUBA1C Q9BQE3 13/20 0.46
▸ TUBB6 Q9BUF5 13/20 0.46
▸ TUBB2B Q9BVA1 13/20 0.46
▸ TUBB1 Q9H4B7 13/20 0.46
▸ EGFR P00533 1/20 0.45
▸ CYP1A2 P05177 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15135524 0.90 TP53 (0.48) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL724236 0.87 TUBB4A (0.56) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL724651 0.86 TUBB4A (0.49) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL725053 0.86 PDGFRB (0.50) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL723931 0.86 TUBB1 (0.57) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL4418355 0.86 TUBB4A (0.57) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL723964 0.85 TUBB4A (0.51) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL724356 0.85 PDGFRB (0.49) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL3469479 0.85 EGFR (0.47) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL4422699 0.85 TUBB4A (0.50) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 — — US disclosed
CN-119548495-A Use of (substituted 1H-imidazol-4-yl) (3, 4, 5-trimethoxyphenyl) methanones for the treatment of coronaviruses 维鲁公司 2025-03-04 — — CN disclosed
EP-4504183-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS Veru Inc. (US) 2025-02-12 — — EP disclosed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 — — US disclosed
CN-118984703-A Methods of treating influenza and poxvirus infections 维鲁公司 2024-11-19 — — CN disclosed
US-20240180879-A1 METHODS OF TREATING INFLAMMATION VERU INC. (US) 2024-06-06 — — US disclosed
EP-4320151-A1 METHODS OF TREATING INFLAMMATION Veru Inc. (US) 2024-02-14 — — EP disclosed
CN-117396505-A Methods of treating inflammation 维鲁公司 2024-01-12 — — CN disclosed
US-20230321045-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS VERU INC. (US) 2023-10-12 — — US disclosed
WO-2023196632-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS VERU INC. (US) 2023-10-12 — — WO disclosed
US-8592465-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-11-26 — — US disclosed
WO-2012027481-A9 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2013-10-10 — — WO disclosed
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-08-01 — — US disclosed
EP-2608671-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-07-03 — — EP disclosed
EP-2542081-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-01-09 — — EP disclosed
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2012-03-22 — — US disclosed
WO-2012027481-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2012-03-01 — — WO disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 — — US disclosed
WO-2011109059-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2011-09-09 — — WO disclosed
US-20090326020-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2009-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187720-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 TUBB4A 296/4885TUBB 213/4885TUBA3C 1166/4885
US-20090326020-A1 COMPOUNDS FOR TREATMENT OF CANCER HCCS, NQO1, CCNY TUBB4A 2060/4885TUBB 2030/4885TUBA3C 2859/4885
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 TUBB4A 296/4885TUBB 213/4885TUBA3C 1166/4885
US-20240180879-A1 METHODS OF TREATING INFLAMMATION IL1B, PYCARD, TUBB1 TUBB4A 13/4885TUBB 6/4885TUBA3C 34/4885
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 TUBB4A 296/4885TUBB 213/4885TUBA3C 1166/4885
US-20230321045-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS TUBB3, TUBB1, TUBB TUBB4A 7/4885TUBB 3/4885TUBA3C 12/4885
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 TUBB4A 296/4885TUBB 213/4885TUBA3C 1166/4885
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 TUBB4A 296/4885TUBB 213/4885TUBA3C 1166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.